Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1985 Mar;142(3):364–368.

Intracavitary Chemotherapy for Malignant Disease Confined to Body Cavities

Maurie Markman 1
PMCID: PMC1306028  PMID: 3887760

Abstract

The direct administration of cytotoxic chemotherapeutic agents into the peritoneal or pleural cavities to treat malignant disease principally involving these regions is based on modeling studies suggesting a major pharmacokinetic advantage for the exposed cavity compared with the plasma. The safety and clinical efficacy of several agents administered directly into body cavities either singly or in combination have now been shown. Additional studies are needed to define optimal drugs, dosages and treatment schedules for the various tumors confined to body cavities. Whether this form of therapy will prove to be superior to standard systemic drug administration will require controlled clinical trials comparing the two treatment methods.

Full text

PDF
364

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Wiernik P. H. Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol. 1981 Sep;8(3):335–343. [PubMed] [Google Scholar]
  2. Anderson C. B., Philpott G. W., Ferguson T. B. The treatment of malignant pleural effusions. Cancer. 1974 Apr;33(4):916–922. doi: 10.1002/1097-0142(197404)33:4<916::aid-cncr2820330405>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  3. Antman K. H., Blum R. H., Greenberger J. S., Flowerdew G., Skarin A. T., Canellos G. P. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980 Mar;68(3):356–362. doi: 10.1016/0002-9343(80)90103-5. [DOI] [PubMed] [Google Scholar]
  4. Bayly T. C., Kisner D. L., Sybert A., Macdonald J. S., Tsou E., Schein P. S. Tetracycline and quinacrine in the control of malignant pleural effusions. A randomized trial. Cancer. 1978 Mar;41(3):1188–1192. doi: 10.1002/1097-0142(197803)41:3<1188::aid-cncr2820410357>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  5. Bergerat J. P., Drewinko B., Corry P., Barlogie B., Ho D. H. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1981 Jan;41(1):25–30. [PubMed] [Google Scholar]
  6. Bergerat J. P., Green C., Drewinko B. Combination chemotherapy in vitro. IV. Response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem Biophys. 1979;3(4):173–180. [PubMed] [Google Scholar]
  7. Casper E. S., Kelsen D. P., Alcock N. W., Lewis J. L., Jr Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983 Mar;67(3):235–238. [PubMed] [Google Scholar]
  8. Dedrick R. L., Myers C. E., Bungay P. M., DeVita V. T., Jr Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978 Jan;62(1):1–11. [PubMed] [Google Scholar]
  9. Drewinko B., Green C., Loo T. L. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1976 Nov;60(11):1619–1625. [PubMed] [Google Scholar]
  10. Dunnick N. R., Jones R. B., Doppman J. L., Speyer J., Myers C. E. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR Am J Roentgenol. 1979 Aug;133(2):221–223. doi: 10.2214/ajr.133.2.221. [DOI] [PubMed] [Google Scholar]
  11. Durand R. E. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res. 1981 Sep;41(9 Pt 1):3495–3498. [PubMed] [Google Scholar]
  12. GREEN T. H., Jr Hemisulfur mustard in the palliation of patients with metastatic ovarian carcinoma. Obstet Gynecol. 1959 Apr;13(4):383–393. doi: 10.1097/00006250-195904000-00001. [DOI] [PubMed] [Google Scholar]
  13. Goldie J. H., Coldman A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727–1733. [PubMed] [Google Scholar]
  14. Goldie J. H., Coldman A. J., Gudauskas G. A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982 Mar;66(3):439–449. [PubMed] [Google Scholar]
  15. Ho D. H., Frei E., 3rd Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944–954. doi: 10.1002/cpt1971126944. [DOI] [PubMed] [Google Scholar]
  16. Holcenberg J., Anderson T., Ritch P., Skibba J., Howser D., Ring B., Adams S., Helmsworth M. Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res. 1983 Mar;43(3):1381–1388. [PubMed] [Google Scholar]
  17. Howell S. B., Chu B. B., Wung W. E., Metha B. M., Mendelsohn J. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest. 1981 Apr;67(4):1161–1170. doi: 10.1172/JCI110130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Howell S. B., Pfeifle C. E., Wung W. E., Olshen R. A. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 1983 Mar;43(3):1426–1431. [PubMed] [Google Scholar]
  19. Howell S. B., Pfeifle C. L., Wung W. E., Olshen R. A., Lucas W. E., Yon J. L., Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982 Dec;97(6):845–851. doi: 10.7326/0003-4819-97-6-845. [DOI] [PubMed] [Google Scholar]
  20. Howell S. B., Taetle R. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep. 1980 Apr-May;64(4-5):611–616. [PubMed] [Google Scholar]
  21. Jones R. B., Collins J. M., Myers C. E., Brooks A. E., Hubbard S. M., Balow J. E., Brennan M. F., Dedrick R. L., DeVita V. T. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res. 1981 Jan;41(1):55–59. [PubMed] [Google Scholar]
  22. Kefford R. F., Woods R. L., Fox R. M., Tatterall M. H. Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study. Med J Aust. 1980 Oct 18;2(8):447–448. doi: 10.5694/j.1326-5377.1980.tb131916.x. [DOI] [PubMed] [Google Scholar]
  23. King M. E., Pfeifle C. E., Howell S. B. Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol. 1984 Jun;2(6):662–669. doi: 10.1200/JCO.1984.2.6.662. [DOI] [PubMed] [Google Scholar]
  24. Kottmeier H. L. Treatment of ovarian cancer with thiotepa. Clin Obstet Gynecol. 1968 Jun;11(2):428–438. [PubMed] [Google Scholar]
  25. Kraft A. R., Tompkins R. K., Jesseph J. E. Peritoneal electrolyte absorption: analysis of portal, systemic venous, and lymphatic transport. Surgery. 1968 Jul;64(1):148–153. [PubMed] [Google Scholar]
  26. Leff A., Hopewell P. C., Costello J. Pleural effusion from malignancy. Ann Intern Med. 1978 Apr;88(4):532–537. doi: 10.7326/0003-4819-88-4-532. [DOI] [PubMed] [Google Scholar]
  27. Niederhuber J. E., Ensminger W. D. Surgical considerations in the management of hepatic neoplasia. Semin Oncol. 1983 Jun;10(2):135–147. [PubMed] [Google Scholar]
  28. Ostrowski M. J., Halsall G. M. Intracavitary bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep. 1982 Nov;66(11):1903–1907. [PubMed] [Google Scholar]
  29. Ozols R. F., Grotzinger K. R., Fisher R. I., Myers C. E., Young R. C. Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res. 1979 Aug;39(8):3202–3208. [PubMed] [Google Scholar]
  30. Ozols R. F., Locker G. Y., Doroshow J. H., Grotzinger K. R., Myers C. E., Young R. C. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979 Aug;39(8):3209–3214. [PubMed] [Google Scholar]
  31. Ozols R. F., Young R. C., Speyer J. L., Sugarbaker P. H., Greene R., Jenkins J., Myers C. E. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982 Oct;42(10):4265–4269. [PubMed] [Google Scholar]
  32. Paladine W., Cunningham T. J., Sponzo R., Donavan M., Olson K., Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976 Nov;38(5):1903–1908. doi: 10.1002/1097-0142(197611)38:5<1903::aid-cncr2820380506>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  33. Pretorius R. G., Hacker N. F., Berek J. S., Ford L. C., Hoeschele J. D., Butler T. A., Lagasse L. D. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983 Dec;67(12):1085–1092. [PubMed] [Google Scholar]
  34. Rosenshein N., Blake D., McIntyre P. A., Parmley T., Natarajan T. K., Dvornicky J., Nickoloff E. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol. 1978 Feb;6(1):106–110. doi: 10.1016/0090-8258(78)90010-0. [DOI] [PubMed] [Google Scholar]
  35. Shea M., Koziol J. A., Howell S. B. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther. 1984 Mar;35(3):419–425. doi: 10.1038/clpt.1984.53. [DOI] [PubMed] [Google Scholar]
  36. Speyer J. L., Collins J. M., Dedrick R. L., Brennan M. F., Buckpitt A. R., Londer H., DeVita V. T., Jr, Myers C. E. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980 Mar;40(3):567–572. [PubMed] [Google Scholar]
  37. Speyer J. L., Myers C. E. The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res. 1980;74:264–269. doi: 10.1007/978-3-642-81488-4_31. [DOI] [PubMed] [Google Scholar]
  38. Speyer J. L., Sugarbaker P. H., Collins J. M., Dedrick R. L., Klecker R. W., Jr, Myers C. E. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981 May;41(5):1916–1922. [PubMed] [Google Scholar]
  39. Taylor A., Jr, Baily N. A., Halpern S. E., Ashburn W. L. Loculation as a contraindication intracavitary 32P-chromic phosphate therapy. J Nucl Med. 1975 Apr;16(4):318–319. [PubMed] [Google Scholar]
  40. Torres I. J., Litterst C. L., Guarino A. M. Transport of model compounds across the peritoneal membrane in the rat. Pharmacology. 1978;17(6):330–340. doi: 10.1159/000136874. [DOI] [PubMed] [Google Scholar]
  41. Tully T. E., Goldberg M. E., Loken M. K. The use of 99mTc-sulfur colloid to assess the distribution of 32P-chromic phosphate. J Nucl Med. 1974 Mar;15(3):190–191. [PubMed] [Google Scholar]
  42. Vider M., Deland F. H., Maruyama Y. Letter: Loculation as a contraindication to intracavitary 32P-chromic phosphate therapy. J Nucl Med. 1976 Feb;17(02):150–151. [PubMed] [Google Scholar]
  43. WEISBERGER A. S., LEVINE B., STORAASLI J. P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955 Dec 31;159(18):1704–1707. doi: 10.1001/jama.1955.02960350004002. [DOI] [PubMed] [Google Scholar]
  44. West G. W., Weichselbaum R., Little J. B. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res. 1980 Oct;40(10):3665–3668. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES